About
Ac Immune Ltd (NASDAQ:ACIU) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 7 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
Mar 19 2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
Mar 13 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
Mar 5 2026
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
Feb 24 2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
Financials
Revenue
$3.57 M
Market Cap
$280.9 M
EPS
-0.88
Translate